2024 Current Fiscal Year Report: Uniform Formulary Beneficiary Advisory Panel

Report Run Date: 03/29/2024 02:16:53 AM

1. Department or Agency	2. Fiscal Year
Department of Defense	2024

3. Committee or Subcommittee	3b. GSA Committee No.
Uniform Formulary Beneficiary Advisory Panel	9484

4. Is this New During Fiscal Year?	5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
No	08/01/2022	08/01/2024	

8a. Was Terminated During FiscalYear?	8b. Specific Termination Authority	8c. Actual Term Date
No		

9. Agency Recommendation for Next FiscalYear	10a. Legislation Req to Terminate?	10b. Legislation Pending?
Continue	Not Applicable	Not Applicable

11. Establishment Authority Statutory (Congress Created)

12. Specific Establishment Authority	13. Effective Date	14. Commitee Type	14c. Presidential?
10 U.S.C. § 1074g(c)	10/05/1999	Continuing	No

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports	No Reports for this FiscalYear

17a. Open	17b. Closed	17c. Partially Closed	Other Activities	17d. Total
0	0	0	0	0

Meetings and Dates

No Meetings

	Current FY	Next FY

18a(1). Personnel Pmts to Non-Federal Members	$0.00	$0.00
18a(2). Personnel Pmts to Federal Members	$0.00	$0.00
18a(3). Personnel Pmts to Federal Staff	$0.00	$0.00
18a(4). Personnel Pmts to Non-Member Consultants	$0.00	$0.00
18b(1). Travel and Per Diem to Non-Federal Members	$0.00	$0.00
18b(2). Travel and Per Diem to Federal Members	$0.00	$0.00
18b(3). Travel and Per Diem to Federal Staff	$0.00	$0.00
18b(4). Travel and Per Diem to Non-member Consultants	$0.00	$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	$0.00	$0.00
18d. Total	$0.00	$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.

20b. How does the Committee balance its membership?

The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.

20c. How frequent and relevant are the Committee Meetings?

Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process.Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending targeted letters to affected beneficiaries during the up to 180-day implementation period. Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.

20d. Why can't the advice or information this committee provides be obtained elsewhere?
Mandated by law to review and comment on recommdenations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.

20e. Why is it necessary to close and/or partially closed committee meetings?
Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.

21. Remarks
Mr. Keith Reed departed in FY 2022 due to becoming a Federal lobbyist July 19, 2022. Title 10, U.S. Code, section 1074g(b), requires the Secretary of Defense to establish a Uniform Formulary Beneficiary Advisory Panel (BAP) under the Federal Advisory Committee Act. The estimated number of Panel meetings is four per year. The relationship between the committee and the decision maker is that no specific reports are submitted to the decision maker. Instead, the committee's advice and recommendations are communicated to the committee's decision maker through its meeting minutes. The committee's decision maker reviews these minutes and makes appropriate decisions for the Department of Defense.

Designated Federal Officer
Paul B. Carby DFO

Committee Members	Start	End	Occupation	Member Designation
Dager, Karen	01/25/2022	01/24/2026	Health Net Federal Services	Special Government Employee (SGE) Member
Dailey, Holly	04/06/2022	04/05/2026	The Association of the United States Army	Special Government Employee (SGE) Member
Du Teil, John	01/25/2022	01/24/2026	United States Army Warrant Officers Association	Special Government Employee (SGE) Member
Guzman, Betsaida	01/25/2022	01/24/2026	Veterans of Foreign Wars	Special Government Employee (SGE) Member
McKeon, Joseph	01/25/2022	01/24/2026	Humana	Special Government Employee (SGE) Member
Meyers, Amanda	04/06/2022	04/05/2026	Military Officers Association	Special Government Employee (SGE) Member
Orfini, Patricia	04/06/2022	04/05/2026	National Family Member Association	Special Government Employee (SGE) Member
Ostrowski, Jon	01/25/2022	01/24/2026	Non-Commissioned Officers Association	Special Government Employee (SGE) Member
Peloquin, Jay	01/25/2022	01/24/2026	Express Scripts, Inc	Special Government Employee (SGE) Member
Schweitzer, Pamela	01/25/2023	01/24/2027	Pharmacist, COA-USPHS	Special Government Employee (SGE) Member

Soucy, Jennifer	01/25/2022	01/24/2026	United States Family Health Plan - Martins Point	Special Government Employee (SGE) Member

Number of Committee Members Listed: 11

Narrative Description

The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	✓
Trust in government	✓
Major policy changes	
Advance in scientific research	
Effective grant making	
Improved service delivery	
Increased customer satisfaction	✓
Implementation of laws or regulatory requirements	✓
Other	

Outcome Comments

NA

What are the cost savings associated with this committee?

	Checked if Applies
None	✓
Unable to Determine	
Under $100,000	
$100,000 - $500,000	
$500,001 - $1,000,000	

$1,000,001 - $5,000,000	☐
$5,000,001 - $10,000,000	☐
Over $10,000,000	☐
Cost Savings Other	☐

Cost Savings Comments
The recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.

What is the approximate Number of recommendations produced by this committee for the life of the committee?
1,168

Number of Recommendations Comments
The Panel made 128 recommendations during FY 2023, to address the FY 2023 DoD Pharmacy and Therapeutics Committee meetings. The Panel makes comments to the DoD Pharmacy and Therapeutics Committee recommendations for changes to the Uniform Formulary, implementation timelines, and prior authorization criteria. To date the Panel has made 1256 recommendations. This includes the 128 recommendations made in FY 2023.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?
100%

% of Recommendations Fully Implemented Comments
The Director, Defense Health Agency, is required to consider the Panel's comments prior to her final decisions.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?
0%

% of Recommendations Partially Implemented Comments
The committee may recommend a shorter or longer implementation period. They may also reject a recommendation. The Director, Defense Health Agency makes the final decision.

Does the agency provide the committee with feedback regarding actions taken to

implement recommendations or advice offered?

Yes ☑ No ☐ Not Applicable ☐

Agency Feedback Comments

Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	☐
Reallocated resources	☐
Issued new regulation	☐
Proposed legislation	☐
Approved grants or other payments	☐
Other	☐

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	☑
Online Agency Web Site	☑
Online Committee Web Site	☑
Online GSA FACA Web Site	☑
Publications	☐
Other	☐

Access Comments

N/A